Antiangiogenic therapy of colorectal cancer: State of the art, challenges and new approaches

Roberta Sarmiento, Raffaele Longo, Giampietro Gasparini

Research output: Contribution to journalArticlepeer-review

Abstract

Advanced colorectal cancer is the first tumor type for which an antiangiogenic agent, namely bevacizumab, has been approved by the Food and Drug Administration for therapy in humans; it has been in use since February 2004. This review paper summarizes and discusses the results obtained with this agent and highlights the main open or controversial issues on antiangiogenic therapy, taking into account that the clinical results obtained are below the expectations, particularly in the adjuvant setting.

Original languageEnglish
JournalInternational Journal of Biological Markers
Volume27
Issue number4
DOIs
Publication statusPublished - Oct 2012

Keywords

  • Angiogenesis
  • Bevacizumab
  • Colorectal cancer

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Cancer Research
  • Oncology
  • Pathology and Forensic Medicine

Fingerprint Dive into the research topics of 'Antiangiogenic therapy of colorectal cancer: State of the art, challenges and new approaches'. Together they form a unique fingerprint.

Cite this